Cargando…
Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects
The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism in vivo, since a specific assay system for GI...
Autores principales: | Takeda, Yasutaka, Fujita, Yukihiro, Yanagimachi, Tsuyoshi, Maruyama, Nobuhiro, Bessho, Ryoichi, Sakagami, Hidemitsu, Honjo, Jun, Yokoyama, Hiroki, Haneda, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260394/ https://www.ncbi.nlm.nih.gov/pubmed/32472669 http://dx.doi.org/10.14814/phy2.14469 |
Ejemplares similares
-
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2020) -
Alternative form of glucose‐dependent insulinotropic polypepide and its physiology
por: Fujita, Yukihiro, et al.
Publicado: (2016) -
Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test
por: Takeda, Yasutaka, et al.
Publicado: (2019) -
Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors
por: Takeda, Yasutaka, et al.
Publicado: (2017) -
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2016)